BioCardia (BCDA) Competitors $1.97 +0.13 (+7.07%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends BCDA vs. ATNM, OCX, ELEV, CALC, LUMO, LTRN, MRKR, TPST, BRNS, and AFMDShould you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Actinium Pharmaceuticals (ATNM), OncoCyte (OCX), Elevation Oncology (ELEV), CalciMedica (CALC), Lumos Pharma (LUMO), Lantern Pharma (LTRN), Marker Therapeutics (MRKR), Tempest Therapeutics (TPST), Barinthus Biotherapeutics (BRNS), and Affimed (AFMD). These companies are all part of the "pharmaceutical products" industry. BioCardia vs. Actinium Pharmaceuticals OncoCyte Elevation Oncology CalciMedica Lumos Pharma Lantern Pharma Marker Therapeutics Tempest Therapeutics Barinthus Biotherapeutics Affimed Actinium Pharmaceuticals (NYSE:ATNM) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, community ranking, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment. Does the media prefer ATNM or BCDA? In the previous week, BioCardia had 5 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 5 mentions for BioCardia and 0 mentions for Actinium Pharmaceuticals. BioCardia's average media sentiment score of 0.58 beat Actinium Pharmaceuticals' score of 0.00 indicating that BioCardia is being referred to more favorably in the news media. Company Overall Sentiment Actinium Pharmaceuticals Neutral BioCardia Positive Does the MarketBeat Community prefer ATNM or BCDA? BioCardia received 11 more outperform votes than Actinium Pharmaceuticals when rated by MarketBeat users. Likewise, 59.26% of users gave BioCardia an outperform vote while only 38.46% of users gave Actinium Pharmaceuticals an outperform vote. CompanyUnderperformOutperformActinium PharmaceuticalsOutperform Votes538.46% Underperform Votes861.54% BioCardiaOutperform Votes1659.26% Underperform Votes1140.74% Do insiders & institutionals have more ownership in ATNM or BCDA? 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 6.0% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 20.0% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, ATNM or BCDA? Actinium Pharmaceuticals has a beta of 0.07, suggesting that its share price is 93% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Do analysts recommend ATNM or BCDA? Actinium Pharmaceuticals currently has a consensus target price of $7.40, indicating a potential upside of 473.64%. BioCardia has a consensus target price of $25.00, indicating a potential upside of 1,169.04%. Given BioCardia's stronger consensus rating and higher possible upside, analysts plainly believe BioCardia is more favorable than Actinium Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80BioCardia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, ATNM or BCDA? BioCardia has lower revenue, but higher earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActinium Pharmaceuticals$81K496.83-$48.82M-$1.39-0.93BioCardia$71K127.19-$11.57M-$4.19-0.47 Is ATNM or BCDA more profitable? Actinium Pharmaceuticals has a net margin of 0.00% compared to BioCardia's net margin of -1,999.77%. BioCardia's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Actinium PharmaceuticalsN/A -100.85% -47.89% BioCardia -1,999.77%N/A -208.38% SummaryBioCardia beats Actinium Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Ad Porter & CompanyVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Get BioCardia News Delivered to You Automatically Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCDA vs. The Competition Export to ExcelMetricBioCardiaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.03M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio-0.4746.7390.1317.20Price / Sales127.19415.011,117.09117.05Price / CashN/A182.1043.1037.85Price / Book-1.773.894.784.78Net Income-$11.57M-$42.21M$120.31M$225.60M7 Day Performance-5.29%-2.15%-1.92%-1.23%1 Month Performance-12.83%1.73%13.65%0.46%1 Year Performance-79.79%16.36%28.34%15.24% BioCardia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCDABioCardia3.3021 of 5 stars$1.97+7.1%$25.00+1,169.0%-79.8%$9.03M$71,000.00-0.4716Analyst ForecastShort Interest ↓Positive NewsGap UpATNMActinium Pharmaceuticals1.2452 of 5 stars$1.23-0.4%$7.40+504.1%N/A$38.22M$81,000.00-0.8849OCXOncoCyte3.2612 of 5 stars$2.25-3.0%$4.42+96.3%-23.2%$37.87M$1.50M0.00120Analyst ForecastELEVElevation Oncology1.9868 of 5 stars$0.64+0.6%$7.20+1,025.0%+30.0%$37.84MN/A-0.7840Analyst ForecastCALCCalciMedica2.9484 of 5 stars$2.80+2.6%$19.33+590.5%-7.1%$37.75MN/A-2.5330Positive NewsLUMOLumos Pharma3.0986 of 5 stars$4.34flat$8.63+98.7%+45.6%$37.54M$2.21M-1.0130High Trading VolumeLTRNLantern PharmaN/A$3.47+0.6%N/A-24.0%$37.42MN/A-1.9420Gap DownMRKRMarker Therapeutics4.0361 of 5 stars$4.19+2.9%$19.00+353.5%-4.8%$37.38M$3.31M0.0060News CoveragePositive NewsTPSTTempest Therapeutics1.8299 of 5 stars$0.85+5.8%$20.00+2,263.5%-80.8%$36.93MN/A0.0020BRNSBarinthus Biotherapeutics1.5315 of 5 stars$0.90-1.4%$5.83+548.1%-66.8%$36.21M$800,000.00-0.61107Gap UpAFMDAffimed4.451 of 5 stars$2.15flat$13.50+527.9%-73.8%$34.62M$8.95M0.0076Analyst RevisionNews Coverage Related Companies and Tools Related Companies ATNM Alternatives OCX Alternatives ELEV Alternatives CALC Alternatives LUMO Alternatives LTRN Alternatives MRKR Alternatives TPST Alternatives BRNS Alternatives AFMD Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BCDA) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCDA Stock Alerts